Abstract
Lipoprotein(a) is a unique form of low-density lipoprotein. It is associated with a high incidence of premature atherosclerotic disease such as coronary artery disease, myocardial infarction, and stroke. Plasma levels of this lipoprotein and its activities are highly variable. This is because of a wide variability in the size of the apolipoprotein A moiety, which is determined by the number of repeats of cysteine-rich domains known as “kringles.” Although the exact mechanism of lipoprotein(a)-induced atherogenicity is unknown, the lipoprotein has been found in the arterial walls of atherosclerotic plaques. It has been implicated in the formation of foam cells and lipid deposition in these plaques. Pharmacologic management of elevated levels of lipoprotein(a) with statins, fibrates, or bile acid sequestrants is ineffective. The newer and emerging lipid-lowering agents, such as the second-generation antisense oligonucleotides, cholesteryl ester transfer protein inhibitors, and proprotein convertase subtilisin/kexin type 9 inhibitors offer the most effective pharmacologic therapy.
Similar content being viewed by others
References
Tipping RW, Ford CE, Simpson LM, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–23.
Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711. https://doi.org/10.1016/j.jacc.2016.11.042.
Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526–37.
Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52(6):1181–7.
Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111–25.
Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016;2(1):1–6. https://doi.org/10.1186/s40842-016-0024-x.
Maranhão RC, Carvalho PO, Strunz CC, et al. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76–84.
Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.
Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2012;125(2):241–9.
Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311–20. https://doi.org/10.1016/S0140-6736(18)31652-0.
Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589–96.
Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263–82.
Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol: A consensus statement from EAS and EFLM. Clin Chem. 2018;64(7):1006–33.
Grundy SM, Stone NJ, Chair V, et al. Cholesterol clinical practice guidelines: executive summary. Circulation. 2018. https://doi.org/10.1161/CIR.0000000000000624.
Miltiadous G, Saougos V, Cariolou M, et al. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Ann Clin Lab Sci. 2006;36(3):353–5.
Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019;1:1–10.
Yahya R, Berk K, Verhoeven A, et al. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. Atherosclerosis. 2019; p. 1–5.
Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160(8):1177–84.
Sahebkar A, Simental-Mendía LE, Watts GF, et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017;15(1):1–14. https://doi.org/10.1186/s12916-017-0787-7.
Herrmann W, Biermann J, Kostner GM. Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol. 1995;76(459):462.
Kooshki A, Taleban FA, Tabibi H, et al. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Ren Fail. 2011;33(9):892–8.
Shinozaki K, Kambayashi J, Kawasaki T, et al. The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein(a) and lipids in patients with vascular disease. J Atheroscler Thromb. 1996;2(2):107–9.
Ballantyne CM, Davidson MH, McKenney JM, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2(2):79–90.
Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non-HDL Cholesterol (from the SEACOAST I Study). Am J Cardiol. 2008;101(10):1428–36.
Chen F, Maccubbin D, Yan L, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013;167(1):225–31. https://doi.org/10.1016/j.ijcard.2011.12.103.
Insull W, Basile JN, Vo AN, et al. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME Study. J Clin Lipidol. 2009;3(2):109–18. https://doi.org/10.1016/j.jacl.2009.02.009.
Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(12):1959–70.
Sahebkar A, Reiner Ž, Simental-Mendía LE, et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664–78.
Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8 SUPPL. 1).
Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008;52(2):124–31.
Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14):1845–52.
Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 1994;14(10):1586–93.
Ferretti G, Bacchetti T, Simental-Mendía LE, et al. Raloxifene lowers plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Cardiovasc Drugs Ther. 2017;31(2):197–208.
Langsted A, Nordestgaard BG. Antisense oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep. 2019;21(8):1–7.
Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III Trials. Arterioscler Thromb Vasc Biol. 2015;35(3):689–99.
Li N, Li Q, Tian XQ, et al. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2014;14(5):367–76.
Tsimikas S. AKCEA-APO(a)-LRx Shows Promise of Reducing Lp(a) Levels in Patients With Preexisting CVD - American College of Cardiology. In: AHA Conference. Chicago, IL. https://www.acc.org/latest-in-cardiology/articles/2018/11/07/15/19/sat-445pm-akcea-apo-lrx-to-lower-lipoprotein-aha-2018. Accessed 14 Oct 2019.
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD [NCT04023552]. Available online from: https://clinicaltrials.gov/ct2/show/NCT04023552. Accessed 2 Sep 2020
Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91(1):109–22. https://doi.org/10.1038/clpt.2011.271/nature06264.
Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27.
Hovingh GK, Kastelein JJP, Van Deventer SJH, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452–60. https://doi.org/10.1016/S0140-6736(15)60158-1.
Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 2016;57(6):1086–96.
O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–92.
McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344–53. https://doi.org/10.1016/j.jacc.2012.03.007.
Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711–5. https://doi.org/10.1016/j.amjcard.2014.05.060.
Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH i and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003.
Cao YX, Liu HH, Li S, et al. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs. 2019;19(1):87–97. https://doi.org/10.1007/s40256-018-0303-2.
Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12).
García-Gómez C, Martín-Martínez MA, Castañeda S, Sanchez-Alonso F, et al. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol. 2017;11(3):749–756.e3.
Ueland T, Kleveland O, Michelsen AE, et al. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. Int J Cardiol. 2019;274:348–50. https://doi.org/10.1016/j.ijcard.2018.06.093.
Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyeride transfer protein inhibitor in homozygous familial hypercholesterolemia. Lancet. 2013;381(9860):40–6.
Sahebkar A, Simental-Mendía LE, Stefanutti C, et al. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198–209. https://doi.org/10.1016/j.phrs.2016.01.030.
Awad K, Mikhailidis DP, Katsiki N, et al. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled Trials. Drugs. 2018;78(4):453–62. https://doi.org/10.1007/s40265-018-0870-1.
Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24(8):729–41.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to conduct this study or prepare this manuscript.
Conflict of interest
Nathaniel Eraikhuemen, Dovena Lazaridis, and Matthew T. Dutton have no conflicts of interest that are directly relevant to the content of this article.
Informed consent
Not applicable.
Ethics approval
Not applicable.
Availability of Data and Material
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Author Contributions
Conceptualization: [Nathaniel Eraikhuemen]. All authors [Nathaniel Eraikhuemen], [Dovena Lazaridis], and [Matthew T. Dutton] contributed to the the literature search, data analysis, and drafted the originaly work. Critical revisions of the work were performed by [Nathaniel Eraikhuemen] and [Dovena Lazaridis]. All authors performed approval of the final submitted version of the manuscript.
Glossary
Glossary
- JUPITER:
-
Rosuvastatin 20 mg versus placebo in prevention of cardiovascular (CV) EventsMENDEL-1: monoclonal antibody against PCSK9 to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults currently not receiving drug therapy for easing lipid levels.
- MENDEL-2:
-
Monoclonal antibody against PCSK9 to reduce elevated LDL-C in subjects currently not receiving drug therapy for easing lipid levels-2.
- LAPLACE-TIMI 57:
-
Low-density lipoprotein cholesterol (LDL-C) assessment with PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy (LAPLACE.
- LAPLACE-2:
-
LDL-C assessment With PCSK9 monoclonal antibody inhibition combined with statin therapy-2.
- RUTHERFORD-1:
-
Reduction of low-density lipoprotein cholesterol (LDL-C) with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder study.
- RUTHERFORD-2:
-
Reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder study-2.
- GAUSS-1:
-
Goal Achievement after utilizing an anti-PCSK9 antibody in statin intolerant subjects.
- GAUSS-2:
-
Goal achievement after utilizing an anti-PCSK9 antibody in statin intolerant subjects-2.
- OSLER-1:
-
Open label study of long term evaluation against LDL-C trial.
- FOURIER:
-
Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk
- ODYSSEY:
-
Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab
Rights and permissions
About this article
Cite this article
Eraikhuemen, N., Lazaridis, D. & Dutton, M.T. Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. Am J Cardiovasc Drugs 21, 255–265 (2021). https://doi.org/10.1007/s40256-020-00437-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-020-00437-7